Drug Trial Radar · NCT04816526
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Dec 1, 2021
Primary completion
Aug 4, 2022
Study completion Nov 3, 2022
Sponsor
- Lead sponsor
- Cartesian TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.
Conditions
- Myeloma Multiple
Interventions
Descartes 08Biological
Car T-cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Stringent Complete ResponseTime frame: 8 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of California Irvine
Orange, California
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.